ARPI-Resistant Prostate Cancer

Yüksel Ürün: KEYNOTE-991 Trial Results in mHSPC Treatment

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article on X:

“KEYNOTE-991: Pembrolizumab plus Enzalutamide and ADT vs Placebo plus Enzalutamide and ADT in treatment-naive mHSPC.

  • Did not improve rPFS.
  • No OS benefit.
  • More toxicity.”

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Authors: C. Gratzke, M. Özgüroğlu, A. Peer, M.A.N. Sendur, M. Retz, J.C. Goh, W. Loidl, G. Jayram, S.-S. Byun, C. Kwak, M. Kwiatkowski, R.M. Kopp, J.C.V. Limón, J.F.E. Penagos, U. De Giorgi, K.M. da Trindade, C. Niu, Y. Liu, C.H. Poehlein, and J.M. Piulats.

You can read the full article on Journal of ESMO Annals of Oncology.

Yüksel Ürün: KEYNOTE-991 Trial Results in mHSPC Treatment

More posts featuring Yüksel Ürün.

A. Peer ADT androgen deprivation therapy C. Gratzke C. Kwak C. Niu C.H. Poehlein cancer Enzalutamide ESMO Annals of Oncology fight against cancer G. Jayram Global fight against cancer J.C. Goh J.C.V. Limón J.F.E. Penagos J.M. Piulats. K.M. da Trindade KEYNOTE-991 Trial M. Kwiatkowski M. Özgüroğlu M. Retz M.A.N. Sendur Metastatic Hormone-sensitive Prostate Cancer mHSPC treatment OncoDaily Oncology pembrolizumab placebo R.M. Kopp rPFS S.-S. Byun U. De Giorgi W. Loidl Y Liu Yüksel Ürün